Search for: "FOREST LABORATORIES"
Results 301 - 320
of 382
Sort by Relevance
|
Sort by Date
8 Nov 2009, 7:44 pm
(IP finance) Gospel, gold diggers and gum trees: How sampling litigation changes the tune (IP Osgoode) Australia A mere collocation - Full Federal Court allows appeal against grant of interlocutory injunction preventing Smith & Nephew entering negative pressure wound therapy market: Smith & Nephew P/L v Wake Forest University Health Sciences (ipwars.com) The Vegemite/iSnack trade mark saga down under: Fiasco or triumph? [read post]
28 Oct 2009, 7:15 am
(The SPC Blog) EU: European Federation of Pharmaceutical Industries and Associations unveils anti-counterfeit authentication system (IP Watch) US: Time Magazine on data exclusivity debate (Patent Docs) US: BIO’s IPCC Conference: Behind the scenes look at patent cases – Mayo v Prometheus; Bilski v Doll; Laboratory Court of Am. [read post]
28 Oct 2009, 6:15 am
(The SPC Blog) EU: European Federation of Pharmaceutical Industries and Associations unveils anti-counterfeit authentication system (IP Watch) US: Time Magazine on data exclusivity debate (Patent Docs) US: BIO's IPCC Conference: Behind the scenes look at patent cases - Mayo v Prometheus; Bilski v Doll; Laboratory Court of Am. [read post]
28 Oct 2009, 6:15 am
(The SPC Blog) EU: European Federation of Pharmaceutical Industries and Associations unveils anti-counterfeit authentication system (IP Watch) US: Time Magazine on data exclusivity debate (Patent Docs) US: BIO's IPCC Conference: Behind the scenes look at patent cases - Mayo v Prometheus; Bilski v Doll; Laboratory Court of Am. [read post]
21 Oct 2009, 9:54 pm
District Court for the Southern District of New York has awarded Infosint $15 million as a reasonable royalty in Infosint's patent dispute with Lundbeck A/S and Forest Laboratories, Inc. over the patent covering Lexapro ®. [read post]
8 Oct 2009, 6:05 am
Have the inventor make a secret side deal (Patent Baristas) US: Governors send letter to Congressional leaders in support of 12-year data exclusivity period (Patent Docs) US Congress urged to act on biosimilars (GenericsWeb) US: Hal Wegner wakes up ACI Biotech Patents Forum in Boston – KSR and biotech claims (BioTechnology Patent Law) Products Amrix (Cyclobenzaprine) – US: Eurand files patent infringement suit in C D California against Anchen following Para… [read post]
7 Oct 2009, 6:44 am
Forest Laboratories Inc. v. [read post]
4 Sep 2009, 5:27 am
§ 1407, Unopposed by Class Action Plaintiffs, but Transfers Class Actions to District not Mentioned by Any of the Parties, the District of Massachusetts Two class actions – one in Missouri and one in New York – were filed against various defendants, including Forest Laboratories and Forest Pharmaceuticals alleging that defendants “engaged in false and misleading promotion of Celexa and Lexapro for pediatric or adolescent use and… [read post]
3 Sep 2009, 9:27 pm
§ 1407, Unopposed by Class Action Plaintiffs, but Transfers Class Actions to District not Mentioned by Any of the Parties, the District of Massachusetts Two class actions – one in Missouri and one in New York – were filed against various defendants, including Forest Laboratories and Forest Pharmaceuticals alleging that defendants “engaged in false and misleading promotion of Celexa and Lexapro for pediatric or adolescent use and sought to induce… [read post]
30 Aug 2009, 12:58 am
Jurors in state court in Orange, Texas, deliberated about two hours before ruling the vehicle wasn't to blame for the death of 13-year-old Forest "Eddie" Ray in 2007. [read post]
11 Aug 2009, 5:38 pm
Photo from Las Alamos National Laboratory. [read post]
15 Jul 2009, 5:15 am
IPAB rejects Novartis’ patent application for Glivec (Intellectual Property Watch) Lescol (Fluvastatin) – Netherlands: No interim relief pending appeal against invalidity, rules District Court of The Hague: Novartis v Mylan and Actavis (PatLit) Levaquin (Levoflaxacin) – Canada: FCA holds generics raising allegations similar to those of previous generics allowed their day in court: Apotex v Janssen-Ortho (Global IP Watch) Lexapro (Escitalopram) – US: Caraco… [read post]
8 Jul 2009, 7:04 am
(Spicy IP) India: Novartis patent rejection by the IPAB: Accessing the decision (Spicy IP) (IAM) India: Likely corruption in the Indian health care sector – Public interest litigation over government shutdown of vaccine production plants to enter contracts with private sector (IP Osgoode) Kenya: Manufacturers, public heath interests clash over anti-counterfeit law; AIDS patients to bring Constitutional challenge (Intellectual Property Watch) (Afro-IP) (Intellectual Property Watch) Spain:… [read post]
19 Jun 2009, 7:36 am
Forest Grove School District v. [read post]
2 Jun 2009, 8:52 am
Here we have a BC based company supplying its homegrown green energy technology to a BC university, with the fuel for the plant coming from the local forest industry. [read post]
1 Jun 2009, 3:36 am
Forest Laboratories, Inc., et al., on the other hand, involves allegations relating to Forest Laboratories Inc.'s marketing of the drugs, and economic damages allegedly caused from the sale of Celexa or Lexapro. [read post]
26 May 2009, 9:54 am
The companies agreeing to the Alabama settlement are: Abbott Laboratories, Schering-Plough Corp., Warrick Pharmaceuticals Corp., TEVA Pharmaceuticals USA, IVAX Corp., IVAX Pharmaceuticals, Barr Laboratories, Aventis Pharmaceuticals, Aventis Behring, ZLB Behring, Sanofi-Synthelabo, Forest Laboratories, Forest Pharmaceuticals, Baxter Healthcare Corp. and Baxter International. [read post]
8 May 2009, 9:12 am
Here are a few of the big lies Chevron told to 60 Minutes: The health impacts of oil used in cosmetics is equivalent to the health impacts of decades of exposure to the toxins left in the water and soil after Texaco dumped more than 19 billion gallons of toxic wastewaters and spilled 16.8 million gallons of crude oil into the Amazon forest. [read post]
1 May 2009, 6:25 pm
“Forest Laboratories set aside $170 million related to a Justice Department investigation into its marketing and promotion of two antidepressants in the fiscal fourth quarter, when net income slid 46 percent to $92.8 million compared with last year’s fourth quarter. [read post]
17 Apr 2009, 12:00 am
Ltd. sues 11 generics companies over Levaquin patents (Law 360) Lexapro (Escitalopram) – Netherlands District court invalidates Lundbeck’s patent EP ‘066 (IPKat) Lexapro (Escitalopram) - Baldwin’s rules explained (The SPC Blog) Lexapro (Escitalopram) – federal district Judge agrees to determine whether Forest Laboratories destroyed key documents (Law 360) Pegasys (PEG interferon alfa 2a) – Roche wins post grant opposition… [read post]
